Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

• Published in: Blood Vol. 94; no. 3; pp. 1086 - 1099
• Main Authors: Leith, Catherine P., Kopecky, Kenneth J., Chen, I-Ming, Eijdems, Lisette, Slovak, Marilyn L., McConnell, Thomas S., Head, David R., Weick, James, Grever, Michael R., Appelbaum, Frederick R., Willman, Cheryl L.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01-08-1999; The Americain Society of Hematology
• Subjects: Acute Disease; Adolescent; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; ATP Binding Cassette Transporter, Subfamily B, Member 1 - biosynthesis; ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics; ATP-Binding Cassette Transporters - biosynthesis; ATP-Binding Cassette Transporters - genetics; Biological and medical sciences; Chemotherapy; Female; Gene Frequency; Hematologic and hematopoietic diseases; Humans; Leukemia, Myeloid - drug therapy; Leukemia, Myeloid - genetics; Leukemia, Myeloid - physiopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins - genetics; Neoplasm Proteins - immunology; Pharmacology. Drug treatments; Prognosis; Treatment Outcome; Vault Ribonucleoprotein Particles - genetics; Vault Ribonucleoprotein Particles - immunology; Human; Prognosis; Acute; Cytology; P Glycoprotein; Malignant hemopathy; Lung resistance protein; Gene expression; Chemotherapy; Treatment; Multiple resistance; Multidrug resistance associated protein 1; Negative therapeutic reaction; Age; Acute myelocytic leukemia
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V94.3.1086.415k32_1086_1099

Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML). Such resistance has been associated with rapid drug efflux mediated by the multidrug resistance gene 1 (MDR1; encoding P-glycoprotein) and more recently with expression of other novel proteins conferring multidrug resistance such as MRP1 (multidrug resistance–associated protein 1) and LRP (lung resistance protein). To determine the frequency and clinical significance of MDR1, MRP1, and LRP in younger AML patients, we developed multiparameter flow cytometric assays to quantify expression of these proteins in pretreatment leukemic blasts from 352 newly diagnosed AML patients (median age, 44 years) registered to a single clinical trial (SWOG 8600). Protein expression was further correlated with functional efflux by leukemic blasts [assessed using two substrates: Di(OC)2and Rhodamine 123] and with the ability of MDR-reversing agents to inhibit efflux in vitro. MDR1/P-glycoprotein expression, which was highly correlated with cyclosporine-inhibited efflux, was noted in only 35% of these younger AML patients, distinctly lower than the frequency of 71% we previously reported in AML in the elderly (Blood89:3323, 1997). Interestingly, MDR1 expression and functional drug efflux increased with patient age, from a frequency of only 17% in patients less than 35 years old to 39% in patients aged 50 years (P = .010). In contrast, MRP1 was expressed in only 10% of cases and decreased with patient age (P = .024). LRP was detected in 43% of cases and increased significantly with increasing white blood cell counts (P = .0015). LRP was also marginally associated with favorable cytogenetics (P = .012) and French-American-British (FAB) AML FAB subtypes (P = .013), being particularly frequent in M4/M5 cases. Only MDR1/P-glycoprotein expression and cyclosporine-inhibited efflux were significantly associated with complete remission (CR) rate (PMDR1 = .012; Pefflux = .039) and resistant disease (RD; PMDR1= .0007; Pefflux = .0092). No such correlations were observed for MRP1 (PCR = .93;PRD = .55) or LRP (PCR = .50; PRD = .53). None of these parameters were associated with overall or relapse-free survival. Unexpectedly, a distinct and nonoverlapping phenotype was detected in 18% of these cases: cyclosporine-resistant efflux not associated with MDR1, MRP1, or LRP expression, implying the existence of other as yet undefined efflux mechanisms in AML. In summary, MDR1 is less frequent in younger AML patients, which may in part explain their better response to therapy. Neither MRP1 nor LRP are significant predictors of outcome in this patient group. Thus, inclusion of MDR1-modulators alone may benefit younger AML patients with MDR1(+) disease.